Ubs Asset Management Americas Inc Bei Gene, Ltd. Transaction History
Ubs Asset Management Americas Inc
- $381 Billion
- Q3 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 3,786 shares of BGNE stock, worth $688,597. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,786
Previous 4,807
21.24%
Holding current value
$688,597
Previous $685,000
23.94%
% of portfolio
0.0%
Previous 0.0%
Shares
25 transactions
Others Institutions Holding BGNE
# of Institutions
252Shares Held
45.3MCall Options Held
292KPut Options Held
119K-
Baker Bros. Advisors LP New York, NY10.6MShares$1.92 Billion25.41% of portfolio
-
Capital International Investors Los Angeles, CA6.43MShares$1.17 Billion0.29% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E95.18MShares$942 Million26.65% of portfolio
-
Primecap Management CO Pasadena, CA4.97MShares$905 Million0.84% of portfolio
-
Baillie Gifford & CO3.71MShares$674 Million0.64% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $18.9B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...